The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells

Sarah L. Heyerdahl, Julian Rozenberg, Louis Jamtgaard, Vikas Rishi, Lyuba Varticovski, Kelly Akah, Dominic Scudiero, Robert H. Shoemaker, Tatiana S. Karpova, Richard Day, James G. McNally, Charles Vinson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The inhibition of DNA binding of basic leucine zipper (B-ZIP) transcription factors is a clinically relevant molecular target. Our laboratory has previously reported two methods of inhibiting B-ZIP DNA binding in solution: 1) an arylstibonic acid compound that binds to the basic region, stabilizes the B-ZIP dimer, and prevents B-ZIP DNA binding and 2) dominant negative proteins, termed A-ZIPs, that heterodimerize with B-ZIP domains in a leucine zipper-dependent manner. To determine if these two agents also inhibit DNA binding in live cells, GFP-tagged B-ZIP domains and mCherry-tagged A-ZIP domains were transfected into NIH3T3 cells to assess protein localization and Fluorescence Recovery After nuclear Photobleaching (FRAP). FRAP, showed that all six GFP-B-ZIP domains examined recovered faster in the nucleus in the presence of drug that we interpret represents an inhibition of DNA binding. Faster recovery in the presence of the A-ZIP was leucine zipper dependent. The arylstibonic also induced a cytoplasmic localization of all B-ZIP domains while the A-ZIPs induced a leucine zipper-dependent cytoplasmic localization. Thus, the change in cellular localization of B-ZIP domains could be used as a high-throughput assay for inhibitors of B-ZIP DNA binding. Additionally, the arylstibonic acid compound was cytostatic in clear cell sarcoma cells, which express a chimera between the B-ZIP domain of ATF-1 and N-terminal activation domain of EWS but not in K562 cells that express a non-B-ZIP containing chimeric protein BCR-ABL. These studies suggest that arylstibonic acid compounds or other small molecules capable of inhibiting B-ZIP DNA binding could be valuable anticancer agents.

Original languageEnglish (US)
Pages (from-to)564-573
Number of pages10
JournalEuropean Journal of Cell Biology
Volume89
Issue number7
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Leucine Zippers
Acids
DNA
Fluorescence Recovery After Photobleaching
Clear Cell Sarcoma
Basic-Leucine Zipper Transcription Factors
Proteins
K562 Cells
Cytostatic Agents

Keywords

  • Antimony
  • Arylstibonic acid
  • B-ZIP domain
  • DNA binding
  • FRAP
  • VBP

ASJC Scopus subject areas

  • Cell Biology
  • Histology
  • Pathology and Forensic Medicine

Cite this

Heyerdahl, S. L., Rozenberg, J., Jamtgaard, L., Rishi, V., Varticovski, L., Akah, K., ... Vinson, C. (2010). The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells. European Journal of Cell Biology, 89(7), 564-573. https://doi.org/10.1016/j.ejcb.2009.11.029

The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells. / Heyerdahl, Sarah L.; Rozenberg, Julian; Jamtgaard, Louis; Rishi, Vikas; Varticovski, Lyuba; Akah, Kelly; Scudiero, Dominic; Shoemaker, Robert H.; Karpova, Tatiana S.; Day, Richard; McNally, James G.; Vinson, Charles.

In: European Journal of Cell Biology, Vol. 89, No. 7, 2010, p. 564-573.

Research output: Contribution to journalArticle

Heyerdahl, SL, Rozenberg, J, Jamtgaard, L, Rishi, V, Varticovski, L, Akah, K, Scudiero, D, Shoemaker, RH, Karpova, TS, Day, R, McNally, JG & Vinson, C 2010, 'The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells', European Journal of Cell Biology, vol. 89, no. 7, pp. 564-573. https://doi.org/10.1016/j.ejcb.2009.11.029
Heyerdahl, Sarah L. ; Rozenberg, Julian ; Jamtgaard, Louis ; Rishi, Vikas ; Varticovski, Lyuba ; Akah, Kelly ; Scudiero, Dominic ; Shoemaker, Robert H. ; Karpova, Tatiana S. ; Day, Richard ; McNally, James G. ; Vinson, Charles. / The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells. In: European Journal of Cell Biology. 2010 ; Vol. 89, No. 7. pp. 564-573.
@article{89f3fedea3314fe290e16644748385c1,
title = "The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells",
abstract = "The inhibition of DNA binding of basic leucine zipper (B-ZIP) transcription factors is a clinically relevant molecular target. Our laboratory has previously reported two methods of inhibiting B-ZIP DNA binding in solution: 1) an arylstibonic acid compound that binds to the basic region, stabilizes the B-ZIP dimer, and prevents B-ZIP DNA binding and 2) dominant negative proteins, termed A-ZIPs, that heterodimerize with B-ZIP domains in a leucine zipper-dependent manner. To determine if these two agents also inhibit DNA binding in live cells, GFP-tagged B-ZIP domains and mCherry-tagged A-ZIP domains were transfected into NIH3T3 cells to assess protein localization and Fluorescence Recovery After nuclear Photobleaching (FRAP). FRAP, showed that all six GFP-B-ZIP domains examined recovered faster in the nucleus in the presence of drug that we interpret represents an inhibition of DNA binding. Faster recovery in the presence of the A-ZIP was leucine zipper dependent. The arylstibonic also induced a cytoplasmic localization of all B-ZIP domains while the A-ZIPs induced a leucine zipper-dependent cytoplasmic localization. Thus, the change in cellular localization of B-ZIP domains could be used as a high-throughput assay for inhibitors of B-ZIP DNA binding. Additionally, the arylstibonic acid compound was cytostatic in clear cell sarcoma cells, which express a chimera between the B-ZIP domain of ATF-1 and N-terminal activation domain of EWS but not in K562 cells that express a non-B-ZIP containing chimeric protein BCR-ABL. These studies suggest that arylstibonic acid compounds or other small molecules capable of inhibiting B-ZIP DNA binding could be valuable anticancer agents.",
keywords = "Antimony, Arylstibonic acid, B-ZIP domain, DNA binding, FRAP, VBP",
author = "Heyerdahl, {Sarah L.} and Julian Rozenberg and Louis Jamtgaard and Vikas Rishi and Lyuba Varticovski and Kelly Akah and Dominic Scudiero and Shoemaker, {Robert H.} and Karpova, {Tatiana S.} and Richard Day and McNally, {James G.} and Charles Vinson",
year = "2010",
doi = "10.1016/j.ejcb.2009.11.029",
language = "English (US)",
volume = "89",
pages = "564--573",
journal = "European Journal of Cell Biology",
issn = "0171-9335",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "7",

}

TY - JOUR

T1 - The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells

AU - Heyerdahl, Sarah L.

AU - Rozenberg, Julian

AU - Jamtgaard, Louis

AU - Rishi, Vikas

AU - Varticovski, Lyuba

AU - Akah, Kelly

AU - Scudiero, Dominic

AU - Shoemaker, Robert H.

AU - Karpova, Tatiana S.

AU - Day, Richard

AU - McNally, James G.

AU - Vinson, Charles

PY - 2010

Y1 - 2010

N2 - The inhibition of DNA binding of basic leucine zipper (B-ZIP) transcription factors is a clinically relevant molecular target. Our laboratory has previously reported two methods of inhibiting B-ZIP DNA binding in solution: 1) an arylstibonic acid compound that binds to the basic region, stabilizes the B-ZIP dimer, and prevents B-ZIP DNA binding and 2) dominant negative proteins, termed A-ZIPs, that heterodimerize with B-ZIP domains in a leucine zipper-dependent manner. To determine if these two agents also inhibit DNA binding in live cells, GFP-tagged B-ZIP domains and mCherry-tagged A-ZIP domains were transfected into NIH3T3 cells to assess protein localization and Fluorescence Recovery After nuclear Photobleaching (FRAP). FRAP, showed that all six GFP-B-ZIP domains examined recovered faster in the nucleus in the presence of drug that we interpret represents an inhibition of DNA binding. Faster recovery in the presence of the A-ZIP was leucine zipper dependent. The arylstibonic also induced a cytoplasmic localization of all B-ZIP domains while the A-ZIPs induced a leucine zipper-dependent cytoplasmic localization. Thus, the change in cellular localization of B-ZIP domains could be used as a high-throughput assay for inhibitors of B-ZIP DNA binding. Additionally, the arylstibonic acid compound was cytostatic in clear cell sarcoma cells, which express a chimera between the B-ZIP domain of ATF-1 and N-terminal activation domain of EWS but not in K562 cells that express a non-B-ZIP containing chimeric protein BCR-ABL. These studies suggest that arylstibonic acid compounds or other small molecules capable of inhibiting B-ZIP DNA binding could be valuable anticancer agents.

AB - The inhibition of DNA binding of basic leucine zipper (B-ZIP) transcription factors is a clinically relevant molecular target. Our laboratory has previously reported two methods of inhibiting B-ZIP DNA binding in solution: 1) an arylstibonic acid compound that binds to the basic region, stabilizes the B-ZIP dimer, and prevents B-ZIP DNA binding and 2) dominant negative proteins, termed A-ZIPs, that heterodimerize with B-ZIP domains in a leucine zipper-dependent manner. To determine if these two agents also inhibit DNA binding in live cells, GFP-tagged B-ZIP domains and mCherry-tagged A-ZIP domains were transfected into NIH3T3 cells to assess protein localization and Fluorescence Recovery After nuclear Photobleaching (FRAP). FRAP, showed that all six GFP-B-ZIP domains examined recovered faster in the nucleus in the presence of drug that we interpret represents an inhibition of DNA binding. Faster recovery in the presence of the A-ZIP was leucine zipper dependent. The arylstibonic also induced a cytoplasmic localization of all B-ZIP domains while the A-ZIPs induced a leucine zipper-dependent cytoplasmic localization. Thus, the change in cellular localization of B-ZIP domains could be used as a high-throughput assay for inhibitors of B-ZIP DNA binding. Additionally, the arylstibonic acid compound was cytostatic in clear cell sarcoma cells, which express a chimera between the B-ZIP domain of ATF-1 and N-terminal activation domain of EWS but not in K562 cells that express a non-B-ZIP containing chimeric protein BCR-ABL. These studies suggest that arylstibonic acid compounds or other small molecules capable of inhibiting B-ZIP DNA binding could be valuable anticancer agents.

KW - Antimony

KW - Arylstibonic acid

KW - B-ZIP domain

KW - DNA binding

KW - FRAP

KW - VBP

UR - http://www.scopus.com/inward/record.url?scp=77951999359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951999359&partnerID=8YFLogxK

U2 - 10.1016/j.ejcb.2009.11.029

DO - 10.1016/j.ejcb.2009.11.029

M3 - Article

VL - 89

SP - 564

EP - 573

JO - European Journal of Cell Biology

JF - European Journal of Cell Biology

SN - 0171-9335

IS - 7

ER -